The Top 5 Biosimilars Articles for the Week of January 13

The Center for Biosimilars® recaps the top stories for the week of January 13, 2020.

Hi, I’m Christina Mattina for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilars articles for the week of January 13, 2020.

Number 5: A recent study is the latest to find that Samsung Bioepis’ biosimilar SB4 works well for the majority of patients who switched from the originator etanercept, Enbrel.

Number 4: The Institute for Clinical and Economic Review released its final report on policy recommendations on the clinical effectiveness and economic value of Janus kinase (JAK) inhibitors for treating rheumatoid arthritis.

Number 3: Two studies recently reported on Hulio, the adalimumab biosimilar marketed and developed by Mylan and its partner Fujifilm Kyowa Kirin Biologics, saying it is equivalent to AbbVie’s reference adalimumab, sold as Humira.

Number 2: In the United States, recent analyses show that biosimilars achieved just 9%, or $91 million, of the $1 billion in cost savings that the Congressional Budget Office projected 10 years ago.

Number 1: An article in JAMA raises concerns that special and accelerated drug approval programs at the FDA may have resulted in a process that approves drugs based on weaker data, without reducing overall drug development time.

To read all of these articles and more, visit